Samarium 153 lexidronam

Drug Profile

Samarium 153 lexidronam

Alternative Names: 153SM samarium ethylenediaminetetramethylene phosphonic acid; CYT 424; Quadramet; Samarium 153 EDTMP; Samarium SM 153 lexidronam pentasodium; Sm 153 EDTMP

Latest Information Update: 15 May 2018

Price : $50 *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Dow Chemical
  • Developer CIS bio international; EUSA Pharma; Lantheus Medical Imaging; Superna Life Sciences
  • Class Analgesics; Inorganic chemicals; Radiopharmaceuticals
  • Mechanism of Action Ionising radiation emitters; Reactive oxygen species stimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Marketed Pain
  • Discontinued Bone metastases; Breast cancer; Multiple myeloma; Osteosarcoma; Prostate cancer; Rheumatoid arthritis

Most Recent Events

  • 02 Apr 2015 Samarium 153 lexidronam is still in phase I/II trials for Multiple myeloma (Combination therapy, Recurrent) in the USA
  • 02 Apr 2015 Samarium 153 lexidronam is still in phase II trials for Prostate cancer in the USA
  • 01 Nov 2014 M.D. Anderson Cancer Center in collaboration with Cytogen complete a phase II trial in Breast Cancer in USA (NCT00429507)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top